5 days ago
Molbio Diagnostics Shares Hit Upper Circuit After Strong IPO Rally
Molbio Diagnostics makes tests that help detect diseases quickly.
Its shares rose sharply after the company entered the stock market.
On 10 September, the shares reached ₹1,509.70 and were locked at the daily 20% upper limit.
This was nearly 87% higher than the IPO price of ₹807.
The company also reported a profit in the latest quarter instead of a loss a year earlier.
Its income grew strongly during the same period.
More people used the company’s Truenat test kits, helping drive the growth.
Experts believe the company has good long-term prospects.
However, they also say investors should be careful because the shares have risen quickly.
Molbio Diagnostics shares hit the 20% upper circuit on 10 September, reaching an all-time high of ₹1,509.70 on the BSE.
The stock has gained nearly 87% from its IPO price of ₹807 per share after listing on 17 August 2026.
Molbio reported a Q1 FY27 consolidated profit of ₹52.74 crore, compared with a loss of ₹23.94 crore a year earlier.
Q1 FY27 total income rose to ₹411.48 crore from ₹100.47 crore, while Truenat test-kit volumes increased to 62.4 lakh units.
The ₹940-crore IPO was subscribed 70.26 times, and experts remain positive while advising investors to stay disciplined after the sharp rally.
- Who
- Molbio Diagnostics, its investors, market experts, and Chief Executive Officer Sriram Natarajan.
- What
- Molbio Diagnostics shares surged to a 20% upper circuit after strong post-IPO gains and improved quarterly results.
- Where
- The shares traded on the BSE and National Stock Exchange; Molbio has facilities in Goa and Visakhapatnam.
- When
- The latest share-price move occurred on Thursday, 10 September; the company listed on 17 August 2026 and reported Q1 FY27 results on 7 September.
- Why
- The rally followed strong investor interest, improved Q1 FY27 profitability and income, and sharply higher Truenat test-kit consumption.
Positive Long-Term Outlook
Caution After Sharp Gains
Growth prospects
Positive Long-Term Outlook
Market experts cited Molbio’s molecular-diagnostics leadership, expansion strategy and favourable industry outlook as reasons for optimism.
Caution After Sharp Gains
The sharp rise since the listing means investors should remain disciplined, according to the experts cited.
Share-price rally
Positive Long-Term Outlook
Strong quarterly results, higher Truenat consumption and the company’s profitable Q1 supported continued investor interest.
Caution After Sharp Gains
The stock’s nearly 87% gain from the IPO price and its 20% upper circuit highlight the risk of chasing rapid gains.
Key facts
- IPO price
- ₹807 per share
- Latest reported share high
- ₹1,509.70 on the BSE
- Q1 FY27 profit
- ₹52.74 crore, versus a ₹23.94-crore loss in Q1 FY26
- Q1 FY27 total income
- ₹411.48 crore, compared with ₹100.47 crore a year earlier
- Truenat volumes
- 62.4 lakh units in Q1 FY27, up from 7.9 lakh units
- IPO size
- Around ₹940 crore
- IPO subscription
- 70.26 times on the final bidding day
Quotes
Sriram Natarajan
Executive Director and Chief Executive Officer of Molbio Diagnostics Ltd
“FY27 is a milestone year for Molbio, marking our transition to a listed company. We have begun the year on a strong note, with healthy growth across both revenue and profitability in Q1”
livemint.com
Sources
Related news
Molbio Diagnostics shares debut with 29% premium
Molbio Diagnostics Shares Fall After Strong Post-Listing Rally
Symbiotec Pharmalab Shares Debut Near Issue Price, Recover Later
Symbiotec Pharmalab Shares Set for Premium Market Debut
Tempsens Instruments Makes Blockbuster Debut With 96% Premium
Stocks in Focus as Corporate Orders, Approvals and Actions Arrive
Indian Markets Consolidate as IPO Activity Dominates Trading Week
Molbio Diagnostics IPO Monday debut; GMP, experts signal gains
